- Home
- TRDA
as 12-17-2024 4:00pm EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 609.7M | IPO Year: | 2021 |
| Target Price: | $23.33 | AVG Volume (30 days): | 105.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.35 - $21.79 | Next Earning Date: | 11-05-2024 |
| Revenue: | $215,232,000 | Revenue Growth: | 146.92% |
| Revenue Growth (this year): | 47.45% | Revenue Growth (next year): | -74.94% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | TRDA | 10% Owner | Dec 10 '24 | Sell | $20.50 | 44,722 | $917,110.96 | 4,402,849 | |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Nov 29 '24 | Sell | $19.98 | 6,000 | $119,948.30 | 73,849 | |
| Sethuraman Natarajan | TRDA | President, Research & Develop. | Nov 29 '24 | Sell | $20.14 | 15,891 | $320,619.70 | 144,997 | |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Nov 11 '24 | Sell | $19.98 | 8,637 | $172,562.08 | 73,849 | |
| Sethuraman Natarajan | TRDA | President, Research & Develop. | Nov 11 '24 | Sell | $20.02 | 4,109 | $82,299.94 | 144,997 | |
| Sethuraman Natarajan | TRDA | President, Research & Develop. | Nov 4 '24 | Sell | $18.56 | 18,219 | $339,280.66 | 144,997 | |
| Sethuraman Natarajan | TRDA | President, Research & Develop. | Oct 16 '24 | Sell | $18.00 | 600 | $10,800.00 | 144,997 | |
| Dowden Nathan J | TRDA | President & COO | Sep 26 '24 | Sell | $16.00 | 847 | $13,552.00 | 125,149 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
TipRanks
11 days ago
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating
MT Newswires
12 days ago
Roth Initiates Entrada Therapeutics at Buy
Zacks
23 days ago
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why
MT Newswires
a month ago
Entrada Therapeutics Insider Sold Shares Worth $339,281, According to a Recent SEC Filing
Simply Wall St.
a month ago
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
a month ago
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.